PHARMACOLOGY UPDATE

Olezarsen Injection (Tryngolza)

Name: Relias Media
Price range: $

February 28, 2025

The U.S. Food and Drug Aministration has approved olezarsen, a first-in-class drug to reduce triglycerides in adults with familial chylomicronemia syndrome. Olezarsen is an antisense oligonucleotide-directed inhibitor of apolipoprotein C-III messenger ribonucleic acid.

Issue Date: February 28, 2025

Table of Contents

Dr. Stephen Brunton, physician editor, reports he is on the speakers bureau for AstraZeneca, the advisory board for Novo Nordisk, the speakers bureau and advisory board for Abbott Diabetes, and is a stockholder with Paracrine. The relevant financial relationships listed for this individual have been mitigated. None of the remaining planners or authors for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Subscription Publication Books & Study Guides Group & Site Licenses State CME/CE Requirements